Byooviz, a biosimilar referencing Lucentis, has been launched in the United States and will be commercially available on July 1, according to a press release.
“Byooviz ushers in a new era of biosimilars into ophthalmology and an alternative for patients and providers. This will be the test balloon for other future biosimilars as providers will evaluate the efficacy and safety of these drugs. Byooviz provides a gold standard drug in a cheaper format, which will be welcome by patients and providers,” OSN Associate Medical Editor Rishi P. Singh, MD, told (Read more...)